Bio-Rad Laboratories (BIO) Liabilities and Shareholders Equity (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $10.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed 0.37% year-over-year to $10.3 billion in Q2 2026; TTM through Jun 2026 was $40.3 billion, a 1.53% increase from a year earlier, with the FY2025 full-year figure at $10.6 billion, up 12.95% from the prior year.
• Liabilities and Shareholders Equity was $10.3 billion for Q2 2026 at Bio-Rad Laboratories, up from $9.8 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $14.4 billion in Q1 2022 and troughed at $9.4 billion in Q4 2024.
• A 5-year average of $11.4 billion and a median of $11.2 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 39.57% in 2022 and rose 12.95% in 2025, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $13.5 billion in 2022, then retreated by 8.91% to $12.3 billion in 2023, then retreated by 23.86% to $9.4 billion in 2024, then gained by 12.95% to $10.6 billion in 2025, then declined by 3.07% to $10.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $10.3 billion (Q2 2026), $9.8 billion (Q1 2026), and $10.6 billion (Q4 2025), per Business Quant data.